The Technology Strategy Board and its Innovation Platform on the Detection

1
The Technology Strategy Board and its Innovation
Platform on the Detection Identification of
Infectious Agents
Dr Penny Wilson
North West Development Agency Warrington24 March
2009
2
A national organisation promoting
technology-enabled innovation for business
benefit, economic growth, and quality of life
3
About us

• An executive NDPB, sponsored by DIUS
• Strong links across government (BERR, DEFRA,
  Health, MOD, DCMS, DCLG etc)
• Partnerships with e.g. research councils, RDAs,
  the devolved administrations, ETI
• Focused on business innovation and the
  application of technology
• Investing 1bn in 2008-2011
• Funded by government departments, research
  councils, devolved administrations and RDAs
• Independent, guided by business-led Governing
  Board
• 94 staff with gtgt 600 years of business experience

4

• Our vision for the UK to be a global leader in
  innovation and a magnet for innovative
  businesses, where technology is applied rapidly,
  effectively and sustainably to create wealth and
  enhance quality of life.

To deliver, partnership is key
5

Our strategy in 3 words
6
The Technology Strategy Board and its Innovation
Platform on the Detection Identification of
Infectious Agents
Dr Penny Wilson
North West Development Agency Warrington24 March
2009
7
1 billion investment over 3 years
2008-9
2010-11
The innovation climate Challenge-led
innovation Technology-inspiredinnovation

8
Criteria for investment

• UK capacity to develop and exploit the technology
  
• The right potential for impact in the right time
  frame
• The size of the global market opportunity
• A clear role for us to add value

9

Technology-inspired innovation

• Keeping the technology pipeline full
• Framework of areas to focus on
• Focus developed through consultation with
  business and government partners
• Each area prioritised by high value opportunities
  for resource investment

10

Technology-inspired innovation

• Key technology areas
• Advanced materials
• Bioscience
• Electronics, photonics and electrical systems
• Information and communication technologies
• High value manufacturing
• Nanotechnology
• Emerging technologies
• Proof of concept

11
Challenge-led innovation

• Energy generation and supply
• Environmental sustainability
• Built environment
• Creative industries
• High value services
• Medicines and healthcare
• Transport
• and Innovation Platforms

12
Innovation platforms

• A co-ordinated approach to stimulating
  innovation.
• It starts with a major policy and societal
  challenge..
• ..builds an understanding of how Government plans
  to use regulation, procurement and other measures
  to address this challenge,
• engages business and the research community to
  identify appropriate responses and development
  needs..
• ..and then invests in UK businesses to deliver
  innovative solutions to the challenge

13

Current innovation platforms

• Network security
• Intelligent transport systemsand services
• Assisted living
• Low carbon vehicles
• Low impact buildings
• Detection identification ofinfectious agents

14
Whats next?

• Immersive Education
• Sustainable Agri-Food Supply Chain
• Water
• Waste
• Stratified Medicine
• Sustainable Aviation
• ??

15
The Innovation Climate

• We will inspire and enable people to play their
  part in the innovation economy
• We use successes within our programmes
• We build networks within communities with similar
  goals
• We support knowledge exchange for individuals

16
Knowledge Transfer Networks

• 24 National networks in fields of technology or
  business application
• Funded by the Technology Strategy Board
• Bringing together business, research bodies and
  the finance community
• to stimulate innovation through exchange of
  knowledge and expertise.
• Total KTN membership circa 45,000

17
Integrated Products Manufacturing
Bioscience for Business
Aerospace and Defence
Chemistry Innovation
UK Displays Lighting
Sensors Instrumentation
Resource Efficiency
Cyber Security
bioProcessUK
Electronics
Materials
Photonics
Food Processing
Nanotechnology
Healthcare Technologies
Modern Built Environment
Industrial Mathematics
Intelligent Transport Systems
Digital Communications
Location Timing
Grid Computing Now!
Creative Industries
Environmental
Low Carbon Fuel Cell Technologies
18
Knowledge Transfer Partnerships

• High calibre, recently-qualified individuals work
  on innovation projects in businesses
• Exchanges knowledge, technical and business
  skills
• Brings new expertise and real benefits to
  companies
• Provides business experience for graduates
• Stimulates business-focused education and
  research in institutions

Successful For each 43 new jobs, 1 million
190 company staff trained, invested 2.97m
increase in profit
19
Research base and business engagement

• Collaborative RD
• 890 projects
• 540 M invested of total 1,200M
• 826 academic partnerships 98 HEIs
• 3000 business partnerships
• RC/TSB working group to develop
  multi-disciplinary projects
• Engaging with universities directly

20
Delivery mechanisms

• CRD
• SBRI
• Micro/Nanotechnology Centres
• EUREKA / EU Framework Programme National Contact
  Points
• Knowledge Transfer Networks
• Knowledge Transfer Partnerships

21
International

• Promoting involvement in EU
• Framework Programme (FP7)
• JTIs, A169s, ERANETs etc
• EUREKA and Eurostars
• Supporting UK global companies
• Helping businesses look outward
• International benchmarking and partnering (US,
  Canada, China, India, EU)

22
New Innovation Platform Detection
Identification of Infectious Agents (DIIA)
23
The Challenge Infectious Diseases

• Infectious diseases account for
• Globally
• 20 of human deaths
• 25 of illness
• UK
• 10 deaths
• 4 hospital admissions
• 35 GP consultations (50 of childrens GP
  consultations)
• Diagnostic testing accounts for
• Globally 1-2 of government healthcare
  expenditures
• UK 5 NHS budget
• Yet influences 60-70 healthcare decisions

24
The Challenge - Infectious Diseases in the UK
25
What does success look like?

• Rapid, early detection
• Rapid, targeted treatment
• Reduce illness and death
• Lower cost

26
Government Response

• April 2006, the Foresight study was published,
  based on findings from 450 experts
• Key technological capabilities needed
• Taking technology to the individual
• Early detection and characterisation of
  resistant/virulent pathogens
• Novel information technology
• High throughput screening
• Feb 2008 meeting with government, industry and
  Technology Strategy Board.
• Broad consensus this work should be taken forward

27
Roadmap for using handheld/portable devices for
the detection, identification and monitoring of
infectious diseases in plants, animals and humans
(Fig. 1)
Growing market in personal healthcare, driven by
devices for management of chronic diseases,
general wellbeing and lifestyle
Mobile telephony and pervasive computing allow
more rapid networking and greater local data and
processing power
Drivers and trends
Nanotechnologies, microfluidics, MEMS, developed
for other markets allow reduction in sensor size
and improved capabilities
Decreasing size and cost of GC-MS - driven by
space flight, environmental and homeland security
Standard platforms agreed
Animal DIM mainly by symptoms, not biomarkers
Wild animal surveillance defines zoonotic
hot-spots. Lab informs design of screening test
ICT type systems mature enabling full integration
of POC devices with global networks
Systems
POC devices for non-ID applications eg. SMBG and
pregnancy tests
Devices for novel human diseases
POC devices emerge for professional use
Animal biomarkers for pathogens
Smart objects
Devices for all known pathogens available. Output
fully integrated into international networks
maximising data utility etc
Applications
Detection of pre-symptomatic disease and host
susceptibility
Devices for increasing numbers of known diseases
available. Trend from stand-alone to ICT
integrated devices and from professional to
non-skilled users
Mobile phones measure pulse, blood pressure etc
Immune signatures of human infectious diseases
emerging
Cheaper microfluidic based biosensor technologies
for nucleic acid and protein determination
Immune signatures of animal infectious diseases
emerging
Technologies
POC technologies available for DIM but limited
Trend from PCR to robust simple amplification
technologies and systems capable of functioning
in extreme environmental conditions
Novel sequencing/detection technologies
Now
Near
10
25-30
20
28
Investment Criteria

• 1. Does the UK have the capability?
• Industry capability, KTN support, UK Centres of
  Excellence
• 2. Is there a large market opportunity?
• UK in vitro diagnostics market 0.5 billion

29
Investment Criteria

• 3. Is the idea ready?
• Healthcare trends
• Infectious disease concern
• Social pressure
• Technology advancements
• 4. Can the Technology Strategy Board make a
  difference?
• Enhance interactions and discussions
• Support trials of the new technologies
• Ensure interoperability and compatibility
• Encourage exploitation abroad

30
Implementation Developing rapid diagnostic
tests

• 1. Human infectious agents
• Tuberculosis
• Sepsis
• Antimicrobial resistance
• Sexually transmitted infections
• 2. Animal infectious agents
• Notifiable diseases
• Endemic diseases
• Public health on farm and abattoir testing

31
Processes

• Disseminate information to all interested and
  relevant parties in the private and public
  sectors
• Establish HLSG and Steering Committee
• Scope existing knowledge and technologies
• Work with DH and DEFRA to define product
  capabilities and specifications
• Determine unmet needs, clinician wish lists
• Commission health econometric studies
• Consider where TSB funding will make the greatest
  impact prioritise
• Produce roadmaps
• Engage with industry through workshops and
  presentations
• Call for proposals/competition

32
System Components
ESRC
Data reduction Reporting
Sample preparation

• Detection System/analysis

Biomarker
ICT
Biosensor
MRC
Bioinformatics
Microfluidics
BBSRC
EPSRC
EPSRC
STFC
STFC
AHRC
BBSRC
NERC
33
www.innovateuk.org
Penny.Wilson_at_tsb.gov.uk